ArticleBMC infectious diseases2026
Antibiotic de-escalation in severe intra-abdominal infections: a single-center retrospective cohort study on safety and prognostic factors.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotic de-escalation is a key antimicrobial stewardship strategy aimed at reducing the ecological and adverse effects of broad-spectrum therapy without compromising efficacy. However, its real-world safety and impact on clinical outcomes in patients with severe intra-abdominal infections (IAIs) remain underexplored.
methodsA single-center, retrospective cohort study was conducted from June 2022 to June 2025. Adults with severe IAIs who received initial broad-spectrum antibiotics and achieved source control within 48 h were included. Patients were stratified into de-escalation and non-de-escalation groups on the basis of the antibiotic management strategy. Propensity score matching (1:1) was used to balance baseline characteristics. The primary outcome was clinical cure at 30 days. Secondary outcomes included 28-day mortality, lengths of ICU and hospital stay, antibiotic duration, and the incidence of secondary infections and Clostridioides difficile infection (CDI).
resultsAmong 405 eligible patients, 212 were matched (106 per group). The de-escalation group had a significantly higher clinical cure rate (79.8% vs. 63.5%; OR 2.24, 95% CI 1.29-3.89; P = 0.004) and lower 28-day mortality (9.6% vs. 21.2%; OR 0.40, 95% CI 0.18-0.88; P = 0.02). De-escalation was also associated with shorter ICU and hospital stays, reduced antibiotic duration, and fewer secondary infections. Multivariable analysis confirmed de-escalation (aOR 2.71, 95% CI 1.48-4.97) and adequate source control (aOR 3.52, 95% CI 1.81-6.85) as independent predictors of clinical cure.
conclusionAntibiotic de-escalation following adequate source control is associated with improved clinical outcomes and reduced mortality in severe IAIs without increasing the risk of complications. These findings support its integration into antimicrobial stewardship programs for this high-risk population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42919194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.